Skip to main content

Global Psoriasis Treatment Market Size 2020-2027 | North America, Europe, Asia-Pacific & Latin America Forecast Report

Written by Customer Service on . Posted in Mergers And Acquisitions.

List of Companies profiled in the Report: AbbVie Inc. (Illinois, United States), Novartis AG (Basel, Switzerland), Johnson & Johnson Services, Inc. (New Jersey, United States), Pfizer Inc., (New York, United States), LEO Pharma A/S (Ballerup, Denmark), Merck & Co., Inc. (New Jersey, United States), Amgen Inc. (California, United States), Eli Lilly and Company (Indiana, United States), CELGENE CORPORATION (New Jersey, United States), UCB S.A. (Brussels, Belgium), Sun Pharmaceutical Industries Ltd. (Mumbai, India), Other prominent players

Pune, India, Nov. 17, 2021 (GLOBE NEWSWIRE) — Global psoriasis treatment market size is projected to reach USD 40.58 billion by the end of 2027. Increasing focus on development of biologics for psoriasis treatment will aid the growth of the overall market in the coming years. According to a report published by Fortune Business Insights, titled “ Psoriasis Treatment Market Size, Share & Covid-19 Impact Analysis, By Drug Class (TNF inhibitors, Interleukins, and Others), By Type (Plaque Psoriasis, Psoriatic Arthritis, and Others), By Route of Administration (Oral, Parenteral/Systemic, and Topical) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2020-2027,” the market was worth USD 20.09 billion in 2019 and will exhibit a CAGR of 9.2% during the forecast period, 2020-2027.

Industry Developments:

May 2019 –Mayne Pharma Group Limited announced that it has received FDA approval for the use of SORILUX Foam for the treatment of plaque psoriasis. The product is used in treatment of psoriasis of the body & scalp in patients aged 12 years and older.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/psoriasis-treatment-market-100600

Psoriasis is a medical condition that directly affects the human skin. The condition is a long term disease that currently has very few or no treatment options. The severity of the disease and inadequate treatment methods will lead to a high emphasis on early detection and treatment of the disease across the world. The increasing research and development activities and high investments in these activities will create several growth opportunities for the companies operating in the market. The symptoms of psoriasis include red patches, itchiness, rashes, and irritation. The increasing medical activities associated with the condition and the growing emphasis on the development of efficient treatment options will emerge in favor of the growth of the overall psoriasis treatment market in the foreseeable future.

North America to Emerge Dominant; Increasing Prevalence of Psoriasis will Aid Growth

The report analyses the latest market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The increasing prevalence of psoriasis and several conditions associated with this disease. The growing demand for novel treatment options for this disease will aid the growth of the regional market. As of 2019, the market in North America was worth 8.48 billion and this value is projected to increase at a considerable pace in the coming years. The market in Asia Pacific is projected to exhibit the highest CAGR in the coming years driven by the presence of several large scale companies in several countries across this region.


To get to know more about the short-term and long-term impact of COVID-19 on this market, please visit: https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600


List of companies profiled in the report:

•              AbbVie Inc. (Illinois, United States)

•              Novartis AG (Basel, Switzerland)

•              Johnson & Johnson Services, Inc. (New Jersey, United States)

•              Pfizer Inc., (New York, United States)

•              LEO Pharma A/S (Ballerup, Denmark)

•              Merck & Co., Inc. (New Jersey, United States)

•              Amgen Inc. (California, United States)

•              Eli Lilly and Company (Indiana, United States)

•              CELGENE CORPORATION (New Jersey, United States)

•              UCB S.A. (Brussels, Belgium)

•              Sun Pharmaceutical Industries Ltd. (Mumbai, India)

•              Other prominent players


Enquire before buying @

https://www.fortunebusinessinsights.com/enquiry/queries/psoriasis-treatment-market-100600


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.